Pharmacology · Erythropoiesis-stimulating agents (ESAs)
Darbepoetin alfa !
A modified, longer-acting erythropoietin that allows less frequent injections for the anaemia of kidney disease and chemotherapy.
Updated 2026-11-01
The figure shows natural human erythropoietin bound to its receptor; darbepoetin alfa is an engineered erythropoietin that binds the same receptor.
Mechanism of action
Darbepoetin alfa is an engineered form of erythropoietin that circulates longer than epoetin alfa. It activates the same erythropoietin receptor and so stimulates red cell production in the same way, with similar efficacy and risks.
- The drug binds the erythropoietin receptor in the marrow
- JAK2–STAT signalling keeps erythroid progenitors alive and dividing
- More reticulocytes, then red cells, are released
- Haemoglobin rises over weeks if iron is available
Pharmacokinetics
- Absorption
- Given intravenously or subcutaneously
- Half-life
- Longer than epoetin alfa, so it is given less often
Indications
- Anaemia of chronic kidney disease Chronic kidney disease →
- Anaemia caused by chemotherapy in non-curative cancer treatment
Adverse effects
Common
- Hypertension
- Swelling of the legs
- Injection-site reactions
Contraindications
- Uncontrolled hypertension
- Pure red cell aplasia after a previous ESA
- Cancer treated with curative intent, or anaemia that can be managed by transfusion (chemotherapy setting)
Key interactions
- Iron (oral or intravenous)
- Needed for the response; iron deficiency is the commonest cause of a poor response
- Heparin during haemodialysis
- More anticoagulation may be needed as the haematocrit rises
What is monitored
- Haemoglobin regularly; the dose is reduced if it rises too fast
- Blood pressure
- Iron status (ferritin, transferrin saturation)
Administration and safety
- Intravenous or subcutaneous injection at longer intervals than epoetin
- Not interchangeable dose for dose with epoetin alfa
Nursing care
- Check blood pressure before each dose and report rises
- Teach the signs of clots: leg swelling, chest pain, sudden weakness or trouble speaking
- In dialysis, report an access that stops working as usual
- Check that iron is replaced and that the haemoglobin target is the lowest that avoids transfusion
Pregnancy and breastfeeding
Data in pregnancy are limited; it is used only when the benefit justifies it.
Test yourself
Think of the answer, then tap the question to see it.
How does darbepoetin differ from epoetin alfa?
It lasts longer, so it is injected less often; efficacy and risks are similar.
Which receptor does it activate?
The erythropoietin receptor.
What happens if haemoglobin rises too fast?
The dose is reduced, because a rapid rise is linked to adverse events.
Related drugs
Related conditions
← Back to the class: Erythropoiesis-stimulating agents (ESAs)
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: Darbepoetin Alfa Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2016); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 45 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.